Select your Country or Region

  • TargetMol | Compound LibraryArgentinaArgentina
  • TargetMol | Compound LibraryAustraliaAustralia
  • TargetMol | Compound LibraryAustriaAustria
  • TargetMol | Compound LibraryBelgiumBelgium
  • TargetMol | Compound LibraryBrazilBrazil
  • TargetMol | Compound LibraryBulgariaBulgaria
  • TargetMol | Compound LibraryCroatiaCroatia
  • TargetMol | Compound LibraryCyprusCyprus
  • TargetMol | Compound LibraryCzechCzech
  • TargetMol | Compound LibraryDenmarkDenmark
  • TargetMol | Compound LibraryEgyptEgypt
  • TargetMol | Compound LibraryEstoniaEstonia
  • TargetMol | Compound LibraryFinlandFinland
  • TargetMol | Compound LibraryFranceFrance
  • TargetMol | Compound LibraryGermanyGermany
  • TargetMol | Compound LibraryGreeceGreece
  • TargetMol | Compound LibraryHong KongHong Kong
  • TargetMol | Compound LibraryHungaryHungary
  • TargetMol | Compound LibraryIcelandIceland
  • TargetMol | Compound LibraryIndiaIndia
  • TargetMol | Compound LibraryIrelandIreland
  • TargetMol | Compound LibraryIsraelIsrael
  • TargetMol | Compound LibraryItalyItaly
  • TargetMol | Compound LibraryJapanJapan
  • TargetMol | Compound LibraryKoreaKorea
  • TargetMol | Compound LibraryLatviaLatvia
  • TargetMol | Compound LibraryLebanonLebanon
  • TargetMol | Compound LibraryMalaysiaMalaysia
  • TargetMol | Compound LibraryMaltaMalta
  • TargetMol | Compound LibraryMoroccoMorocco
  • TargetMol | Compound LibraryNetherlandsNetherlands
  • TargetMol | Compound LibraryNew ZealandNew Zealand
  • TargetMol | Compound LibraryNorwayNorway
  • TargetMol | Compound LibraryPolandPoland
  • TargetMol | Compound LibraryPortugalPortugal
  • TargetMol | Compound LibraryRomaniaRomania
  • TargetMol | Compound LibrarySingaporeSingapore
  • TargetMol | Compound LibrarySlovakiaSlovakia
  • TargetMol | Compound LibrarySloveniaSlovenia
  • TargetMol | Compound LibrarySpainSpain
  • TargetMol | Compound LibrarySwedenSweden
  • TargetMol | Compound LibrarySwitzerlandSwitzerland
  • TargetMol | Compound LibraryTaiwan,ChinaTaiwan,China
  • TargetMol | Compound LibraryThailandThailand
  • TargetMol | Compound LibraryTurkeyTurkey
  • TargetMol | Compound LibraryUnited KingdomUnited Kingdom
  • TargetMol | Compound LibraryUnited StatesUnited States
  • TargetMol | Compound LibraryOther CountriesOther Countries
Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty
Filter
Applied FilterClear all
TargetMol | Tags By Target
  • Autophagy
    (1)
  • IκB/IKK
    (1)
  • Mitophagy
    (1)
  • PD-1/PD-L1
    (13)
  • PROTACs
    (1)
  • Sirtuin
    (1)
  • Others
    (33)
Filter
Search Result
Results for "

pd 173955-analog1

" in TargetMol Product Catalog
  • Inhibitors & Agonists
    54
    TargetMol | Activity
  • Peptide Products
    3
    TargetMol | inventory
  • Inhibitory Antibodies
    2
    TargetMol | natural
  • PROTAC Products
    1
    TargetMol | composition
  • Recombinant Protein
    24
    TargetMol | Activity
  • Antibody Products
    6
    TargetMol | inventory
PD 173955-Analog1
T71912185039-99-0
PD 173955-Analog1 is a potent c-Src inhibitor known to have activity against a variety of cancers including colon, lung, head and neck carcinoma.
  • $1,520
6-8 weeks
Size
QTY
PD-1-IN-22
T123792349372-98-9In house
PD-1-IN-22 is a potent inhibitor of the programmed cell death-1 (PD-1) programmed cell death-ligand 1 (PD-L1) interaction, with an IC50 of 92.3 nM.
  • $117
In Stock
Size
QTY
PD-1/PD-L1-IN-9
T96512628506-54-5In house
PD-1 PD-L1-IN-9, with an IC50 of 3.8 nM, is a potent and orally active inhibitor of the PD-1 PD-L1 interaction. It enhances the immune cells' ability to kill tumor cells and demonstrates significant antitumor activity in vivo in a CT26 mouse model.
  • $55
In Stock
Size
QTY
TargetMol | Inhibitor Sale
PD-1-IN-17
T123771673560-66-1In house
PD-1-IN-17 is an inhibitor of programmed cell death-1 (PD-1). PD-1-IN-17 inhibits 92% splenocyte proliferation at 100 nM.
  • $110
35 days
Size
QTY
Anti-Mouse PD-1 Antibody (RMP1-14)
T78269
RMP1-14 is an IgG1-like immunoglobulin and anti-Mouse PD-1 antibody that blocks PD-1/PD-L1 signaling.
  • $99
In Stock
Size
QTY
PD-1/PD-L1-IN-10
T96162487550-41-2
PD-1 PD-L1-IN-10 is an orally active PD-1 PD-L1 inhibitor with an IC50 of 2.7 nM, demonstrating potent anticancer efficacy.
  • $44
In Stock
Size
QTY
TargetMol | Inhibitor Sale
Josiphos SL-J009-1 Pd G3
T67259
Josiphos SL-J009-1 Pd G3 has a wide range of applications in life science related research.
    7-10 days
    Inquiry
    PD-1/PD-L1-IN 3 TFA (1629654-95-0 free base)
    TP1463
    PD-1/PD-L1-IN 3 TFA inhibits the binding of human PD-1 to PD-Ll with an IC50 of 9 nM.
    • Inquiry Price
    Size
    QTY
    PD-1/PD-L1-IN-32
    T79576
    PD-1 PD-L1-IN-32 (compound A56) is a potent inhibitor of PD-1 PD-L1 with an IC50 value of 2.4 nM, demonstrating significant anticancer activity. It effectively suppresses tumor growth in the hPD-L1 MC38 humanized mouse model and exhibits negligible toxicity to the normal functions of the mice [1].
    • Inquiry Price
    Size
    QTY
    Dasatinib analog-1
    T846871174416-41-1
    Dasatinib analog-1 (compound 5826) demonstrates inhibition of CYP3A4 activity, presenting a K_i value of 5.4 μM, and effectively prevents the formation of glutathione adducts [1].
    • Inquiry Price
    8-10 weeks
    Size
    QTY
    PD-L1-IN-1
    T61574
    PD-L1-IN-1, a powerful PD-L1 inhibitor, demonstrated an IC50 of 115 nM. By forming a robust bond with the PD-L1 protein, PD-L1-IN-1 effectively suppressed tumor growth by enhancing the antitumor immune activity of peripheral blood mononuclear cells in co-cultures with PD-L1 expressing cancer cells (PC9 and HCC827 cells). It significantly elevated the release of interferon γ and induced apoptosis in cancer cells, while exhibiting minimal cytotoxicity in healthy cells [1].
    • $862
    10-14 weeks
    Size
    QTY
    PD-1-IN-17 TFA
    T63256
    PD-1-IN-17 TFA is a potent inhibitor of programmed cell death-1 (PD-1), effectively inhibiting 92% of splenocyte proliferation at a concentration of 100 nM.
    • $1,520
    10-14 weeks
    Size
    QTY
    PD-1/PD-L1-IN-27
    T726802891831-47-1
    PD-1 PD-L1-IN-27 is a potent inhibitor of PD-1 PD-L1, with an IC50 of 134 nM, and demonstrates antitumor effects with minimal T cell cytotoxicity. It activates CD8+ T cells and mitigates T cell exhaustion [1].
    • $1,520
    8-10 weeks
    Size
    QTY
    PD-1/PD-L1-IN-28
    T726912499965-07-8
    PD-1/PD-L1-IN-28, an inhibitor of the PD-1/PD-L1 signaling pathway (IC 50 = 0.744 µM), demonstrates promising research potential in tumor immunity. This immune checkpoint inhibitor effectively blocks the interaction within the pathway, offering insights into cancer treatment strategies.
    • $1,520
    6-8 weeks
    Size
    QTY
    PD-1-IN-25
    T871202413100-40-8
    • Inquiry Price
    10-14 weeks
    Size
    QTY
    CE3F4 analog 1
    T396062141967-43-1
    CE3F4 analog 1 is an analogue of CE3F4. It is a chemical compound utilized in various [scientific applications] due to its unique properties, notably in (radical scavenging) and (oxidation-reduction) processes. It plays a significant role in advanced (catalysis), (pharmaceutical) research, and (material science) due to its stability and reactivity.
    • $95
    5 days
    Size
    QTY
    LY88074 analog 1
    T13763183060-99-3
    LY88074 analog 1, a benzothiophene compound with nitrogen-containing non-basic side chains, can be utilized either independently or alongside estrogen or progestin. This agent is effective for mitigating post-menopausal symptoms, including osteoporosis, cardiovascular-related pathological conditions, and estrogen-dependent cancer.
    • $1,520
    6-8 weeks
    Size
    QTY
    PD-1-IN-20
    T12378
    PD-1-IN-20 [476690-36-9] is the less active enantiomer of PD-1-IN-1 [1346528-06-1].
    • Inquiry Price
    Size
    QTY
    PD-1/PD-L1-IN-31
    T78755
    PD-1 PD-L1-IN-31 is a potent inhibitor of PD-1 PD-L1 (IC50=2.2 nM) that enhances IFN-γ secretion and activates the immune response of peripheral blood mononuclear cells (PBMCs), leading to the inhibition of tumor cells [1].
    • Inquiry Price
    Size
    QTY
    PD-1/PD-L1-IN-33
    T796432975602-78-7
    PD-1 PD-L1-IN-33 (Compound N11), a PD-1 PD-L1 inhibitor with an IC50 of 6.3 nM, effectively impedes the interaction between PD-1 and PD-L1. It enhances T-cell proliferation, activation, and infiltration within tumor environments, thereby exhibiting immunomodulatory and anticancer properties [1].
    • $1,670
    8-10 weeks
    Size
    QTY
    PD-1/PD-L1-IN-14
    T619292499965-12-5
    PD-1 PD-L1-IN-14 (compound 17) is an inhibitor of PD-1 PD-L1 interaction (IC50=27.8 nM) that promotes PD-L1 dimerization, endocytosis, and degradation.
    • $1,520
    6-8 weeks
    Size
    QTY
    PD-1/PD-L1-IN-17
    T62501
    PD-1 PD-L1-IN-17 (Compound P20) is a potent PD-1 PD-L1 inhibitor (IC50: 26.8 nM) and a promising lead compound for the development of inhibitors of PD-1 PD-L1 interactions, with potential applications in cancer disease research.
    • $1,520
    10-14 weeks
    Size
    QTY
    PD-1/PD-L1-IN-26
    T726682966090-78-6
    PD-1 PD-L1-IN-26 (Compound II-14) is a potent PD-1 PD-L1 inhibitor with an IC50 of 0.0380 μM. It enhances the immune microenvironment by promoting CD4+ T cell infiltration into tumor tissues, suggesting its potential application in cancer research [1].
    • $1,520
    8-10 weeks
    Size
    QTY
    PD-1/PD-L1-IN 5
    T621932170209-51-3
    PD-1 PD-L1-IN 5 is a potent inhibitor of the PD-1 PD-L1 protein protein interaction (IC50 ≤ 100 nM).
    • $1,520
    6-8 weeks
    Size
    QTY
    PD-1/PD-L1-IN 3 TFA
    T73642
    PD-1 PD-L1-IN 3 TFA, a macrocyclic peptide, serves as a potent and selective inhibitor of the PD-1 PD-L1 interaction. By directly binding to PD-L1, it disrupts PD-L1's binding with PD-1 and CD80, exhibiting IC50 values of 5.60 nM and 7.04 nM, respectively. It is utilized in the research of numerous illnesses, such as cancer and infectious diseases [1].
    • Inquiry Price
    Size
    QTY
    ML120 analog 1
    T86908445426-74-4
      10-14 weeks
      Inquiry
      PD-1/PD-L1-IN-22
      T636072159063-12-2
      PD-1 PD-L1-IN-22, a small molecule inhibitor (IC50: 0.732 μM), blocks PD-1 PD-L1 protein-protein interactions and can be utilized to study cancer, infectious diseases, and autoimmune diseases.
      • $1,520
      8-10 weeks
      Size
      QTY
      Nucleoside-Analog-1
      T19485876707-99-2
      Nucleoside-Analog-1 is a 4′-Azidocytidine analogue, used to against Hepatitis C virus replication.
      • $198
      6-8 weeks
      Size
      QTY
      PD-1/PD-L1-IN-20
      T640862159138-01-7
      PD-1 PD-L1-IN-20 is a small molecule inhibitor of PD-1 PD-L1 protein-protein interaction, blocking the interaction with an IC50 of 5.29 nM. PD-1 PD-L1-IN-20 can be used to study cancer, infectious diseases, and autoimmune diseases.
      • $1,520
      6-8 weeks
      Size
      QTY
      CYP51/PD-L1-IN-1
      T79738
      CYP51 PD-L1-IN-1 (compound L11), a quinazoline with antifungal properties, inhibits CYP51 (IC50: 0.884 μM) and PD-L1 (IC50: 0.083 μM), induces early apoptosis in the fungal cell cycle, decreases intracellular IL-2, NLRP3, and NF-κBp65 protein levels, causes mitochondrial damage and ROS accumulation, leading to fungal lysis and cell death [1].
      • Inquiry Price
      Size
      QTY
      COH34 analog 1
      T10858314248-24-3
      COH34 analog 1 is a COH34 oxidation analogue that can be used to synthesize active compounds.
      • $39
      In Stock
      Size
      QTY
      PD-1/PD-L1-IN-23
      T726752597056-04-5
      PD-1 PD-L1-IN-23 is a potent, orally active ester prodrug of L7, a benzooxadiazole derivative, that functions as an inhibitor of PD-1 PD-L1. It has undergone biological evaluation for its inhibitory effects on PD-L1, showing significant antitumor effects in both syngeneic tumor models and PD-L1 humanized mice.
      • $2,420
      10-14 weeks
      Size
      QTY
      PD-1/PD-L1-IN-25
      T633292768759-52-8
      PD-1 PD-L1-IN-25, an inhibitor of PD-1 PD-L1 interaction (IC50: 16.17 nM), effectively activates anti-tumor immunity in T cells within PBMCs and can be utilized in cancer research.
      • $1,520
      6-8 weeks
      Size
      QTY
      Thiamine diphosphate analog 1
      T195792606-90-8
      Thiamine diphosphate analog 1, an analog of Thiamine diphosphate (the active form of vitamin B1 and a universal cofactor in key cellular pathways), mirrors the structure and potentially the function of its prototype.
      • $1,520
      Backorder
      Size
      QTY
      PD-1-IN-18
      T123861673534-97-8
      PD-1-IN-18 is a PD1 inhibitor of the signaling pathway and functions as an immunomodulator.
      • $1,670
      6-8 weeks
      Size
      QTY
      Melan-A/MART-1 analog
      T81825204060-45-7
      [Leu27]-Melan-A, MART-1 (26-35), is a biologically active peptide modified by substituting leucine for alanine at position 27, which enhances its HLA-A*0201 binding, immunogenicity, and antigenicity compared to the natural peptide. Pyroglutamyl (pGlu) peptides, arising from the spontaneous cyclization of glutamine (Q) or glutamic acid (E) at the N-terminus, are a recognized subset of peptides that may confer increased stability due to the hydrophobic γ-lactam ring of pGlu. These pGlu peptides are typically included during peptide purity assessments in HPLC analysis.
      • Inquiry Price
      Size
      QTY
      PD-1/PD-L1-IN-15
      T63614
      PD-1 PD-L1-IN-15 is a potent PD-1 PD-L1 inhibitor (IC50: 60.1 nM) with demonstrated investigational potential for tumor immunotherapy.
      • $1,520
      10-14 weeks
      Size
      QTY
      PD-1-IN-24
      T399042360909-50-6
      PD-1-IN-24 (compound 1) is an orally active PD-1 inhibitor.
        7-10 days
        Inquiry
        PD-1/PD-L1-IN-13
        T72670
        PD-1/PD-L1-IN-13 is a potent immune checkpoint PD-1/PD-L1 inhibitor with an IC50 value of 10.2 nM for PD-1/PD- L1 interaction.PD-1/PD-L1-IN-13 promotes CD8+ T-cell activation and delays tumour growth in a Hepa1-6 homozygous mouse model.
        • $3,920
        10-14 weeks
        Size
        QTY
        PD-1-IN-17 (TFA) (1673560-66-1 free base)
        T12377L
        PD-1-IN-17 TFA is a inhibitor of programmed cell death-1 (PD-1) .
        • Inquiry Price
        Size
        QTY
        PD-1/PD-L1-IN-34
        T792052924403-17-6
        PD-1 PD-L1-IN-34 (Compound (1S,2S)-A25) effectively inhibits the PD-1 PD-L1 interaction (IC50 = 0.029 μM) and demonstrates selective binding affinity to PD-L1 (KD = 0.1554 μM), resulting in the activation of the immune microenvironment and suppression of tumor growth [1].
        • $1,370
        8-10 weeks
        Size
        QTY
        PROTAC PD-1/PD-L1 degrader-1
        T401122447066-37-5
        PROTAC PD-1 PD-L1 degrader-1, a Cereblon E3 ligand-based compound, is a PD-1 PD-L1 PROTAC that effectively inhibits the PD-1 PD-L1 interaction with an IC50 of 39.2 nM. It restores the suppressed immune response in a co-culture model of Hep3B OS-8 hPD-L1 cells and CD3 T cells and moderately decreases PD-L1 protein levels through a lysosome-dependent mechanism.
        • $296
        In Stock
        Size
        QTY
        PD-1/PD-L1-IN-29
        T727212665734-13-2
        PD-1 PD-L1-IN-29 (S4-1) is a potent inhibitor of the PD-1 PD-L1 interaction with an IC50 value of 6.1 nM. It effectively binds to PD-L1, promoting its dimerization and internalization, enhancing its localization to the endoplasmic reticulum, and demonstrating anticancer activity.
        • $1,520
        6-8 weeks
        Size
        QTY
        PD-L1/PD-1-IN-1
        T871252753642-49-6
        • Inquiry Price
        10-14 weeks
        Size
        QTY
        PD-1/PD-L1-IN-16
        T63948
        PD-1 PD-L1-IN-16, a potent inhibitor of PD-1 PD-L1 (IC50: 53.2 nM), has demonstrated research potential for tumor immunotherapy.
        • $1,520
        10-14 weeks
        Size
        QTY
        Cryptophycin analog 1
        T860951260431-28-4
          10-14 weeks
          Inquiry
          PD-1/PD-L1-IN 5 TFA
          T123802170209-52-4
          PD-1 PD-L1-IN 5 is an inhibitor of PD-1 PD-L1 protein-protein interaction with an IC50 of ≤100 nM.
          • $1,520
          Backorder
          Size
          QTY
          PD-1/PD-L1-IN 6
          T619682393983-76-9
          PD-1 PD-L1-IN 6 (compound A13) is a potent inhibitor of PD-1 PD-L1 interaction (IC50 = 132.8 nM) with outstanding immunoregulatory activity. In a Hep3B OS-8 hPD-L1 and CD3 T cell co-culture model, PD-1 PD-L1-IN 6 significantly elevates interferon-γ secretion without significant toxic effects. Additionally, in a T cell-tumor co-culture model, PD-1 PD-L1-IN 6 restores the immune response.
          • $1,520
          6-8 weeks
          Size
          QTY
          Ecteinascidin-Analog-1
          T11151874758-58-4
          Ecteinascidins are a family of tetrahydroisoquinoline alkaloids known for their antitumor and antimicrobial activities. [Ecteinascidin-Analog-1] is a valuable intermediate for the synthesis of Ecteinascidin analogues.
          • $1,149
          Backorder
          Size
          QTY
          PD-1/PD-L1-IN-30
          T727242171558-14-6
          PD-1/PD-L1-IN-30 is a PD-1/PD-L1 binding inhibitor, with an IC 50 value of 0.018 μM. PD-1/PD-L1-IN-30 can be used for research of cancers and other related diseases .
          • $1,140
          10-14 weeks
          Size
          QTY